Feb 10, 2022 / 02:30PM GMT
Michael Schmidt - Guggenheim Partners - Analyst
All right, hello and welcome. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim. It is my great pleasure to introduce the next company, Kymera. With us today, we have Nello Mainolfi, the CEO, as well as Jared Gollob, Chief Medical Officer. Welcome, and thanks for joining us.
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President & CEO
Thanks, Michael.
Questions and Answers:
Michael Schmidt - Guggenheim Partners - AnalystSo we'll jump right into Q&A. So maybe to start out with, the number of companies with in-house TPD platforms or part of that interest in the space has expanded significantly in recent years, including small private companies, public pure plays and then large pharma companies as well. Can you talk about the Kymera technology platform in context of protein degradation in general and how you've positioned the company in the category?
Nello Mainolfi - Kymera Therapeutics, Inc. -